The HeartFlow FFRCT Analysis is the first non-invasive diagnostic tool that aids clinicians in determining, vessel by vessel, both the extent of an artery’s narrowing and the impact that the narrowing has on blood flow to the heart.
By non-invasively identifying which patients do and do not need intervention, clinicians can reduce unnecessary invasive testing, reduce healthcare system costs and improve patient quality of life.
The National Institute for Health and Care Excellence (NICE) provides national guidance and quality standards to improve health and social care within the UK’s National Health Service (NHS).
NICE issued a Technology Assessment (MTG32) in February 2017 endorsing the use of the HeartFlow® FFRCT Analysis to help physicians determine the cause of stable chest pain in patients. This guidance follows the Chest Pain Guidelines (CG95) issued in November 2016, recommending non-invasive coronary CT angiography (CTCA) as the initial diagnostic test for patients with stable chest pain.
In April 2021, NICE released an updated review of MTG32 which found the following:
IMPORTANT NOTICE: As part of the MedTech Funding Mandate starting on 1 April 2021, the HeartFlow FFRCT Analysis is available to order via the NHS Supply Chain catalogue and managed by the Medical IT Departmental Software and Hardware Solutions Framework, within NHS Supply Chain: Large Diagnostic Capital Equipment including Mobile and Services. More information on this can be found through the NHS Supply Chain website or you can download the Order Guide here.
* Required fields
REFERENCES
The information provided by the HeartFlow Analysis is intended to be used in conjunction with the patient’s clinical history, symptoms, and other diagnostic tests, as well as the clinician’s professional judgement. The HeartFlow Analysis may not be appropriate for all patients. See indications for use for more information. The HeartFlow Analysis, featuring the FFRCT Analysis, RoadMap™ Analysis and Plaque Analysis has received FDA Clearance in the United States of America. The FFRCT Analysis is CE Marked in Europe and the United Kingdom and approved in Japan and Canada. The HeartFlow Analysis, featuring FFRCT Analysis, RoadMap™ Analysis and Plaque Analysis is commercially available in the United States. The FFRCT Analysis is commercially available in Europe, Japan, Canada, and the United Kingdom.
© 2023 HeartFlow, Inc. | HeartFlow and the HeartFlow logo, CT-Flow and the CT-Flow logo, are registered trademarks of HeartFlow, Inc. Additionally, RoadMap is claimed as a trademark of HeartFlow, Inc. www.heartflow.com | 331 E Evelyn Ave, Mountain View, CA 94041
*Required fields
If you would like to request to have the HeartFlow Analysis available at a location near you, please submit your information below with details of the institution. We will share this information with the institution, but it will not guarantee HeartFlow will become available.
*Required fields
オンライン提出フォームから研究助成金を申請してください。
HeartFlow FFRCT 分析は、有資格の臨床医による臨床的に安定した症状のある冠状動脈疾患患者への使用を目的とした個別化された心臓検査です。 HeartFlow Analysis によって提供される情報は、資格のある臨床医が患者の病歴、症状、その他の診断検査、および臨床医の専門的判断と組み合わせて使用することを目的としています。
ハートフロー分析に関する追加の適応情報については、次のサイトをご覧ください。www.heartflow.com/indications.
さらに質問がある場合は、このメッセージを閉じてフォームに記入するか、サポート チームにお電話ください。: 877.478.3569.
The HeartFlow FFRCT Analysis is a personalized cardiac test indicated for use in clinically stable symptomatic patients with coronary artery disease by qualified clinicians. The information provided by the HeartFlow Analysis is intended to be used by qualified clinicians in conjunction with the patient’s history, symptoms, and other diagnostic tests, as well as the clinician’s professional judgement.
For additional indication information about the HeartFlow Analysis, please visit www.heartflow.com/indications.
If you have additional questions, close out of this message to complete our form or call our support team: 877.478.3569.Please use our online submission form on the Clinical Research Page to apply for research grants.
Thank you for your interest!
Executive Vice President and Chief Medical Officer
Campbell brings a wealth of experience to HeartFlow, where he serves as the Chief Medical Officer. Prior to joining HeartFlow, he was the Chief Scientific Officer and Global Head of Research and Development at Cordis Corporation, Johnson & Johnson, where he was responsible for leading investments and research in cardiovascular devices. Prior to Cordis, he was Associate Professor of Medicine at Harvard Medical School and the Harvard-M.I.T. Division of Health Sciences and Technology, and Director of the Cardiac Catheterization and Experimental Cardiovascular Interventional Laboratories at Brigham and Women’s Hospital. He served as Principal Investigator for numerous interventional cardiology device, diagnostic, and pharmacology trials, is the author of numerous journal articles, chapters, and books in the area of coronary artery and other cardiovascular diseases, and was the recipient of research grant awards from the NIH and AHA.
He received his A.B. from Harvard College and his M.D. from Harvard Medical School.
本情報は日本国内の医療関係者を対象とした情報提供サイトです。
一般の方に対する情報提供を目的としたものではございません。
あなたは医療関係者ですか？